Your browser is no longer supported. Please, upgrade your browser.
Settings
ATXI Avenue Therapeutics, Inc. daily Stock Chart
ATXI [NASD]
Avenue Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.40 Insider Own12.20% Shs Outstand9.65M Perf Week32.00%
Market Cap31.84M Forward P/E- EPS next Y-1.40 Insider Trans0.53% Shs Float6.01M Perf Month20.00%
Income-24.20M PEG- EPS next Q-0.33 Inst Own2.10% Short Float0.28% Perf Quarter-21.62%
Sales- P/S- EPS this Y-385.10% Inst Trans- Short Ratio0.33 Perf Half Y-25.00%
Book/sh0.49 P/B6.73 EPS next Y32.70% ROA-132.60% Target Price9.50 Perf Year-37.26%
Cash/sh0.92 P/C3.58 EPS next 5Y- ROE-167.30% 52W Range2.08 - 5.90 Perf YTD-8.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-44.07% Beta-
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low58.62% ATR0.62
Employees2 Current Ratio2.10 Sales Q/Q- Oper. Margin- RSI (14)53.79 Volatility54.07% 22.26%
OptionableNo Debt/Eq0.00 EPS Q/Q-57.50% Profit Margin- Rel Volume3.49 Prev Close3.50
ShortableYes LT Debt/Eq0.00 EarningsAug 10 Payout- Avg Volume51.10K Price3.30
Recom1.50 SMA2011.47% SMA50-1.67% SMA200-17.14% Volume178,212 Change-5.71%
Aug-27-18 01:45PM  ATXI: Second Quarter 2018 Results Zacks Small Cap Research
Aug-14-18 07:30AM  Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire -5.32%
Aug-02-18 10:29AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters -17.26%
09:40AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters
Jun-19-18 08:30AM  Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference GlobeNewswire
Jun-12-18 09:30AM  ATXI: KOL Call with Drs. Singla and Minkowitz on IV Tramadol Zacks Small Cap Research -6.09%
Jun-06-18 08:30AM  Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain GlobeNewswire
May-23-18 07:25AM  Blog Exposure - Avenue Therapeutics Reported Positive Results from Pivotal Phase-3 Trial of IV Tramadol ACCESSWIRE
May-21-18 08:59AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain GlobeNewswire
May-14-18 10:30AM  ATXI: 1Q:18 Update Confirms Timeline Zacks Small Cap Research
May-03-18 07:30AM  Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire -5.06%
Apr-10-18 01:20PM  ATXI: No Pain? We See a Gain; Developing Tramadol Zacks Small Cap Research
Mar-28-18 08:00AM  Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol GlobeNewswire
Mar-05-18 08:00AM  Avenue Therapeutics to Present at March Investor Conferences GlobeNewswire
Mar-01-18 07:30AM  Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
Feb-09-18 10:00AM  Avenue Therapeutics, Inc. (Nasdaq: ATXI) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Feb-06-18 08:30AM  Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor Conference GlobeNewswire
Jan-02-18 08:00AM  Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain GlobeNewswire +5.80%
Nov-09-17 07:30AM  Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights GlobeNewswire +5.79%
Sep-27-17 08:00AM  Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain GlobeNewswire
Aug-15-17 08:00AM  Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer) GlobeNewswire -7.09%
Aug-11-17 07:30AM  Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
Jul-03-17 01:02PM  Here's the Latest on Four New Biotech IPOs TheStreet.com
08:00AM  Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics GlobeNewswire
Jul-02-17 09:50AM  IPOs This Week: A Single Offering on Tap After 8 IPOs Last Week 24/7 Wall St.
Jun-30-17 11:30AM  Avenue Therapeutics Completes Initial Public Offering GlobeNewswire
Jun-28-17 08:20AM  Blue Apron Pricing To Heat Up Crazy IPO Week: Investing Action Plan Investor's Business Daily
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSENWALD LINDSAY A MDDirectorJun 08Buy4.345,23422,71625,234Jun 11 05:37 PM
Herskowitz NeilDirectorApr 25Buy3.801,0003,80052,500Apr 25 04:30 PM
Herskowitz NeilDirectorOct 17Buy5.011,0005,01051,500Oct 18 12:19 PM